
GoodRx stock rebounds with growth momentum but remains risky, warranting a cautious neutral rating.
GoodRx has recovered from a low of $2.50 per share, showing signs of renewed growth and better consumer engagement. New product offerings have helped drive recent positive developments for the company. However, despite these improvements, the stock's...

